The BTKi rollercoaster in MS continues to surprise

The BTKi rollercoaster in MS continues to surprise

Author: Nikita Shah, Beyond Neurology The rollercoaster in the MS fairground has taken another sharp turn. Tolebrutinib has missed its primary endpoint in the Phase 3 PERSEUS trial in PPMS, and the already delayed FDA decision for its nrSPMS indication now looks...